Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 4/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 10/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25858332 | 1.00 | GLS (0.50) | GLSOPRK1MEN1POLBKMT2A | |
| SCHEMBL21738023 | 1.00 | GLS (0.50) | GLSOPRK1MEN1POLBKMT2A | |
| SCHEMBL25858331 | 1.00 | GLS (0.50) | GLSOPRK1MEN1POLBKMT2A | |
| SCHEMBL21737953 | 0.86 | GLS (0.46) | GLSOPRK1MEN1POLBKMT2A | |
| SCHEMBL21737961 | 0.84 | GLS (0.57) | GLSMEN1POLBKMT2ASMPD3 | |
| SCHEMBL21737956 | 0.84 | GLS (0.57) | GLSMEN1POLBKMT2ASMPD3 | |
| SCHEMBL21724985 | 0.80 | GLS (0.52) | GLSSMPD3HRH3TSHR | |
| SCHEMBL25859743 | 0.79 | GLS (0.49) | GLSMEN1POLBKMT2ASMPD3 | |
| SCHEMBL25859744 | 0.79 | GLS (0.49) | GLSMEN1POLBKMT2ASMPD3 | |
| SCHEMBL21738022 | 0.75 | GLS (0.41) | GLSMEN1POLBKMT2ASMPD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702414-B2 | Thiadiazole IRAK4 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702414-B2 | Thiadiazole IRAK4 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| WO-2020036986-A1 | THIADIAZOLE IRAK4 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702414-B2 | Thiadiazole IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | GLS 2423/4885OPRK1 2533/4885MEN1 2601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.